Search Results for: LCK

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
SH2B3 SH2B adaptor protein 3
  • Regulation of KIT signaling
  • Negative regulation of FLT3
  • Factors involved in megakaryocyte development and platelet production
  • Pazopanib
  • Type I diabetes mellitus
SH2D1A SH2 domain containing 1A
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
SH3BP2 SH3 domain binding protein 2
  • Cherubism
SMAD2 SMAD family member 2
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Dexfosfoserine
  • Colorectal cancer
SOS1 SOS Ras/Rac guanine nucleotide exchange factor 1
  • SOS-mediated signalling
  • SOS-mediated signalling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Signalling to RAS
  • Signalling to RAS
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • NCAM signaling for neurite out-growth
  • G alpha (12/13) signalling events
  • Activation of RAC1
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Interleukin-15 signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
SQSTM1 sequestosome 1
  • NRIF signals cell death from the nucleus
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • PINK1-PRKN Mediated Mitophagy
  • Interleukin-1 signaling
  • Pexophagy
  • Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
UBE3A ubiquitin protein ligase E3A
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Prader-Willi and Angelman syndromes, including: Angelman syndrome (AS); Prader-Willi syndrome (PWS)
ZAP70 zeta chain of T cell receptor associated protein kinase 70
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • Staurosporine
  • Fostamatinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
ACP1 acid phosphatase 1
  • Adenine
  • 4-Nitrophenyl Phosphate
ADAM15 ADAM metallopeptidase domain 15
  • Degradation of the extracellular matrix
  • Invadopodia formation
AJUBA ajuba LIM protein
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
ARHGAP17 Rho GTPase activating protein 17
  • Rho GTPase cycle
ASB9 ankyrin repeat and SOCS box containing 9
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
AXL AXL receptor tyrosine kinase
  • VEGFA-VEGFR2 Pathway
  • Fostamatinib
  • Gilteritinib
BCAR1 BCAR1 scaffold protein, Cas family member
  • Downstream signal transduction
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
C1QTNF2 C1q and TNF related 2
CCR5 C-C motif chemokine receptor 5
  • Binding and entry of HIV virion
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
  • Maraviroc
  • AMD-070
  • CCR5 mAb
  • Leronlimab
  • Aplaviroc
  • Vicriviroc
  • Ibalizumab
  • INCB-9471
CD2 CD2 molecule
  • Cell surface interactions at the vascular wall
  • Alefacept
  • Siplizumab
CD247 CD247 molecule
  • Muromonab

Page 3 out of 8 pages